Pancreatic Cancer Trial, Recruiting NCT06526442 Sponsor: Yu Shi Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06526442
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give written consent to participate
  • People who are 18 years of age or older
  • People who have no history of cancer outside of the pancreas
  • People who did not have a bile duct drainage procedure before surgery
  • People who have confirmed pancreatic cancer (PDAC) based on tissue removed during surgery
  • People who survived at least three months after surgery and have been followed up for at least six months

Who may not be able to join:

  • People whose tissue samples from surgery cannot be reviewed again by the research team
  • People whose MRI scan results are not usable — for example, due to problems with the scan data, difficulty holding their breath during the scan, pain that made the scan impossible to complete, or equipment issues during the scan
  • People whose tumour measured less than 1.0 cm (about the size of a small pea)
  • People who withdrew from or dropped out of follow-up care after joining

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yu Shi, MD.PhD., Shengjing Hospital

Phone: 8618940259980

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Yu Shi
Registry
ClinicalTrials.gov
Start date
9 October 2020
Est. completion
1 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Analyzing the measurement accuracy of MRE.; Radiological assessment of tumor stiffness.; Evaluation of tumor response to chemotherapy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov